Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No stone unturned in UK PPRS negotiations

This article was originally published in Scrip

Executive Summary

The UK department of healthis leaving no stone unturned during its negotiations on a new pharmaceutical price regulation scheme. It has written to NHS Trusts to gather information on medicines dispensed at home although prescribed in secondary care (hospitals). These products may have bypassed the pharmacy information systems which are being used to collect information on drug prescribing in hospitals. The growth of medicines expenditure in secondary care is significantly higher than in community care, the department points out. It also notes that the headline agreement with the industry signed in June called for a price cut of 2% for medicines if the actual rate of growth in the drugs bill in primary and secondary care in England exceeds 6.7% in either 2008 or in 2009. As the NHS branded drugs bill in primary and secondary care currently stands at £8 billion, the savings the government would get if this additional 2% is triggered would be substantial, the DoH comments.

You may also be interested in...

Pipeline Watch: Phase III Readouts For Seladelpar, Fasinumab And Carbetocin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Fertility Business And Mavenclad Held Back By COVID-19 But Recovery Signs

Merck KGaA’s pharmaceutical sales were adversely affected by the COVID-19 pandemic in the second quarter, but the Process Solutions part of its life sciences division, products from which support vaccine developers, had a good quarter, and a potential dual Toll-like receptor inhibitor, M5049, entered Phase II.

Evotec Links Up With Secarna On Cutting-Edge Antisense Technology

Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts